{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:34:19Z","timestamp":1788885259101,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Aspirin has been the cornerstone of antiplatelet therapy in patients with acute coronary syndromes and is well accepted and recommended by several major healthcare organizations. A combination of aspirin and a P2Y12 inhibitor, commonly known as dual antiplatelet therapy, is recommended in patients with coronary stent implantation to reduce the risk of stent thrombosis and ischemic events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>We recently cared for an adult male who presented with an acute coronary syndrome who had a history of Reye syndrome during childhood. During this admission, he was rechallenged with low-dose aspirin for the first time since his diagnosis of Reye syndrome as a child after aspirin therapy. There have been various case reports in children and adults who have been rechallenged with aspirin within days to weeks after the initial diagnosis of Reye syndrome. These reports show mixed results in children and adults regarding the return of Reye syndrome upon aspirin rechallenge shortly after initial aspirin exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This, to our knowledge, appears to be the first report of a low-dose aspirin rechallenge 30 years later in life in an adult patient with a history of Reye syndrome while receiving aspirin therapy during childhood.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajhp\/zxz276","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T17:47:23Z","timestamp":1575308843000},"page":"123-127","source":"Crossref","is-referenced-by-count":8,"title":["Aspirin rechallenge in an adult patient previously diagnosed with Reye syndrome"],"prefix":"10.1093","volume":"77","author":[{"given":"BrookeAnne G","family":"Magrum","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry K","family":"Pickworth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,1]]},"reference":[{"issue":"18 Suppl 2","key":"2020010803580345900_CIT0001","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1161\/CIR.0000000000000252","article-title":"Part 1: executive summary: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care","volume":"132","author":"Neumar","year":"2015","journal-title":"Circulation."},{"key":"2020010803580345900_CIT0002","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"2020010803580345900_CIT0003","doi-asserted-by":"crossref","first-page":"e004368","DOI":"10.1161\/CIRCINTERVENTIONS.116.004368","article-title":"Aspirin desensitization in patients with coronary artery disease: results of the multicenter ADAPTED registry (Aspirin Desensitization in Patients with Coronary Artery Disease)","volume":"10","author":"Rossini","year":"2017","journal-title":"Circ Cardiovasc Interv."},{"key":"2020010803580345900_CIT0004","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(63)90554-3","article-title":"Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood","volume":"2","author":"Reye","year":"1963","journal-title":"Lancet."},{"key":"2020010803580345900_CIT0005","first-page":"223","article-title":"Reye\u2019s syndrome in an adult patient","volume":"144","author":"Kirkpatrick","year":"1986","journal-title":"West J Med."},{"key":"2020010803580345900_CIT0006","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000026274","article-title":"Epidemiology of Reye\u2019s syndrome, United States, 1991\u20131994: comparison of CDC surveillance and hospital admission data","volume":"19","author":"Sullivan","year":"2000","journal-title":"Neuroepidemiology."},{"key":"2020010803580345900_CIT0007","first-page":"750","volume-title":"MMWR Morb Mortal Wkly Rep","author":"Centers for Disease Control and Prevention","year":"1997"},{"key":"2020010803580345900_CIT0008","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00148581-200709030-00008","article-title":"Aspirin and Reye syndrome: a review of the evidence","volume":"9","author":"Schr\u00f6r","year":"2007","journal-title":"Paediatr Drugs."},{"key":"2020010803580345900_CIT0009","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7326\/0003-4819-80-1-74","article-title":"Aspirin hepatitis","volume":"80","author":"Wolfe","year":"1974","journal-title":"Ann Intern Med."},{"key":"2020010803580345900_CIT0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1542\/peds.76.2.202","article-title":"Reye syndrome associated with aspirin therapy for systemic lupus erythematosus","volume":"76","author":"Hansen","year":"1985","journal-title":"Pediatrics."},{"key":"2020010803580345900_CIT0011","first-page":"823","article-title":"Is non-therapeutic aspirin use in children a problem in South Africa?","volume":"101","author":"Donald","year":"2011","journal-title":"S Afr Med J."},{"key":"2020010803580345900_CIT0012","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3476(78)81252-9","article-title":"Hepatoxicity with encephalopathy associated with aspirin therapy in rheumatoid arthritis","volume":"93","author":"Ulshen","year":"1978","journal-title":"J Pediatr."},{"key":"2020010803580345900_CIT0013","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1001\/jama.1989.03420170061031","article-title":"New epidemiologic evidence confirming that bias does not explain the aspirin\/Reye\u2019s syndrome association","volume":"261","author":"Forsyth","year":"1989","journal-title":"JAMA."},{"key":"2020010803580345900_CIT0014","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists\u2019 (ATT) Collaboration","year":"2009","journal-title":"Lancet."},{"key":"2020010803580345900_CIT0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/s13063-017-2277-9","article-title":"Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial","volume":"18","author":"Baos","year":"2017","journal-title":"Trials."},{"key":"2020010803580345900_CIT0016","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/2\/123\/31745970\/zxz276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/2\/123\/31745970\/zxz276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T11:46:13Z","timestamp":1665143173000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/77\/2\/123\/5648981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,12,1]]},"published-print":{"date-parts":[[2020,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz276","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1,15]]},"published":{"date-parts":[[2019,12,1]]}}}